The British Journal of Anaesthesia (BJA) has published a new study, the largest ever positive Randomised Clinical Trial (RCT) on Goal-Directed Haemodynamic Therapy(GDHT) using Deltex Medical’s ODM system. The results demonstrate that even

Ewan Phillips, Deltex Medical’s Chief Executive, commented: “Complications after surgery are unpleasant, expensive to treat and reduce patients’ post-operative survival. The ability to eliminate over half of these is of

Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, this morning announced that its French distributor has been awarded a new tender to supply hospitals in Paris

Mid January saw Deltex supporting the EBPOM (Evidence-based perioperative medicine) organisation at its first meeting of 2018. Entitled “Current Initiatives, Research and the Role of Hemodynamic Monitoring” the event was

The government should help SMEs to reward their advances with quicker mass adoption by the NHS, according to Andy Mears, Managing Director of Deltex Medical Group plc (LON:DEMG) Companies can seek grant funding or tax breaks ranging from R&D credits

Using data from 150 of its own patients, a “top ten” U.S. hospital is to adopt Deltex’s Oesophageal Doppler Monitoring (ODM) system. Ranked in the top ten hospitals in the USA,

Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has today announced the addition of a major new hospital in the USA. The hospital is a University